Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes by Elad Moisseiev et al.
MEDICAL OPHTHALMOLOGY
Pharmacokinetics of bevacizumab after topical
and intravitreal administration in human eyes
Elad Moisseiev & Michael Waisbourd & Elad Ben-Artsi &
Eliya Levinger & Adiel Barak & Tad Daniels & Karl Csaky &
Anat Loewenstein & Irina S. Barequet
Received: 20 June 2013 /Revised: 26 September 2013 /Accepted: 1 October 2013 /Published online: 31 October 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background Topical bevacizumab is a potential treatment
modality for corneal neovascularization, and several recent
studies have demonstrated its efficacy. No previous study of
the pharmacokinetics of topical bevacizumab has been
performed in human eyes. The purpose of this study is to
investigate the pharmacokinetics of topical administration of
bevacizumab in human eyes, and also to compare the
pharmacokinetics of intravitreal bevacizumab injections with
previously reported data.
Methods Twenty-two (22 eyes) were included in this study,
and divided into four groups: eight patients received topical
bevacizumab and aqueous samples were obtained 1 hour later
during cataract extraction surgery (group 1), eight patients
received topical bevacizumab and vitreous samples were
obtained 1 day later during pars-plana vitrectomy (PPV)
(group 2), three patients received intravitreal bevacizumab
and vitreous samples were obtained during PPV (group 3).
Vitreous samples from three patients who received no
bevacizumab served as controls (group 4). All samples
underwent enzyme-linked immunosorbent assay to detect
bevacizumab.
Results No bevacizumab was detected in the aqueous or
vitreous of any topically treated eyes. The mean vitreal half-
life for intravitreally injected bevacizumab was 4.9 days in
four non-vitrectomized eyes and 0.66 days in one previously
vitrectomized eye.
Conclusions Topically administered bevacizumab does not
penetrate the cornea into the anterior chamber and vitreous
cavity, indicating that topical use for treating corneal
neovascularization has minimal risk of intraocular penetration
and adverse events related to intraocular vascular endothelial
growth factor inhibition. The half-life following intravitreal
bevacizumab injection measured in this study is comparable
to that of previous reports, and includes the first demonstration
of a significantly reduced half-life following intravitreal
injection in a previously vitrectomized eye.
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Introduction
Bevacizumab (Avastin®, Genentech, San Francisco, CA,
USA) is a recombinant humanized monoclonal
immunoglobulin antibody specifically directed against human
vascular endothelial growth factor (VEGF). It is currently the
most widely used anti-VEGF agent in ophthalmology [1, 2].
Bevacizumab is administered intravitreally, most commonly
for the treatment of neovascular age-related macular
degeneration (AMD), diabetic retinopathy, and retinal vein
occlusions [3]. Several studies have demonstrated the efficacy
of topical bevacizumab administration for the treatment of
corneal neovascularization (NV) in both experimental animal
models [4–7] and human patients [8–10].
There are only a few pharmacokinetic studies on topical
bevacizumab, and they were performed solely in experimental
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animal models. Nomoto et al. [11] reported minimal aqueous
concentration (0.6±0.6 ng/ml) after 1 week of topical
administration of 25 mg/ml bevacizumab 6 times daily in
rabbit eyes. Yoeruek et al. [12] applied bevacizumab 25 mg/
ml drops every minute for 30 minutes to rabbit corneas, and
the aqueous penetration after this mega-dose of bevacizumab
was minimal, as demonstrated by the fact that the detected
amount of bevacizumab was lower by a factor of over 1,000
compared with the initial dose. Dastjerdi et al. [13] reported
minimal penetration of topical bevacizumab in normal mice
corneas. Others have shown that corneal penetration of
bevacizumab was greater in mice with corneal NV and in
those with denuded corneal epithelium, and that it can be
detected in the aqueous, vitreous, serum, and even in the
contralateral eye following subconjunctival injection in
several animal models [11, 13, 14]. Kim et al. [14] postulated
that intraocular penetration of bevacizumab after
subconjunctival injection occurs through the sclera and
systemic circulation.
The purpose of this study was to conduct what, to the best
of our knowledge, is the first evaluation of the
pharmacokinetics of topical bevacizumab in human eyes.
We also compared our findings on the pharmacokinetics of
intravitreal bevacizumab injection to previously reported data.
Methods
Study subjects
The study protocol followed the tenets of the Declaration of
Helsinki, and was approved by the Institutional Review Board
of the Tel Aviv Medical Center. All patients agreed to
participate after a thorough explanation of the nature of the
study, and gave their written informed consent to participate
prior to study entry. This prospective study was conducted at
the Department of Ophthalmology of the Tel Aviv Medical
Center. All patients volunteered to participate in it, and were
recruited from among patients scheduled for elective surgery
at our department. They were divided into three groups
according to bevacizumab treatment protocol and their
subsequent surgery (Table 1): topical bevacizumab and
subsequent cataract extraction (group 1), topical bevacizumab
and subsequent pars plana vitrectomy (PPV) (group 2), and
intravitreal bevacizumab and subsequent PPV (group 3).
Control samples were obtained from three additional patients
who underwent PPV and had never received any previous
treatment with bevacizumab (group 4).
All 22 patients were 18 years or older, and none had
corneal neovascularization or epithelial defects prior to PPV
or cataract surgery. Only one eye of each patient was included
for analysis. The demographic and clinical data that were
recorded included age, gender, previous ocular history,
previous administration of bevacizumab of any kind,
indication for surgery, time between administration of
bevacizumab and sampling, and details of the surgery.
Bevacizumab administration
The study participants were divided into four groups. The
group 1 patients were treated with topical bevacizumab
25 mg/ml: they received a total of four drops, with 10-
minute intervals between drops, 1 hour prior to cataract
extraction surgery. The group 2 patients received four drops
of topical bevacizumab 25 mg/ml on the day before PPV
surgery (once every 6 hours), and an additional four drops
1 hour prior to undergoing surgery at 10-minute intervals.
Two patients in group 2 had been treated with intravitreal
bevacizumab prior to their inclusion in this study. All group
1 and 2 patients were instructed to perform punctal occlusion
for at least 60 seconds after instillation of the bevacizumab
drops. The group 3 patients received an intravitreal injection
of bevacizumab 1.25mg/0.05 ml prior to undergoing PPV: the
administration of bevacizumab was indicated as part of their
treatment, since they all underwent PPV for the removal of
vitreous hemorrhage (VH) secondary to proliferative diabetic
retinopathy (PDR). The time between bevacizumab injection
and vitreous sampling differed between patients in group 3.
The topical and intravitreal bevacizumab administered in
this study were prepared under sterile conditions in the
pharmacy at our institution. Topical bevacizumab was
administered from bottles containing 12 drops of
Table 1 Bevacizumab treatment
protocols, surgery type and
sampling site for each study
group
• Serum samples were also
obtained at the time of surgery in
two patients from group 2 and one
from group 3.
Group n Treatment protocol Surgery Sampling site
1 8 Topical — four drops of bevacizumab 25 mg/ml,
one drop every 10 minutes 1 hour prior to surgery
Cataract extraction Aqueous
2 8 Topical — four drops of bevacizumab 25 mg/ml,
one drop every 6 hours 1 day before surgery,
and another four drops, one every 10 minutes
1 hour prior to surgery
Pars plana vitrectomy Vitreous
3 3 Intravitreal — injection of bevacizumab
1.25 mg/0.05 ml
Pars plana vitrectomy Vitreous
4 3 None Pars plana vitrectomy Vitreous
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bevacizumab 25 mg/ml. Syringes containing bevacizumab
1.25 mg/0.05 ml were used for intravitreal administration.
Both preparations were refrigerated at 4 °C for no longer than
5 days prior to use.
Surgical procedures and sampling
Cataract extract ion surgery was performed by
phacoemulsification using the Infinity Vision System (Alcon
Laboratories Inc., Fort Worth, TX, USA). All PPVs were 23-
gauge, performed using the 23-gauge Constellation Vision
System (Alcon Laboratories Inc., Fort Worth, TX, USA). No
intraoperative or postoperative complications were
encountered. Undiluted aqueous samples were drawn
from the group 1 eyes through a paracentesis using a
cannula prior to irrigation, while undiluted vitreous
samples were drawn through a sclerotomy using the
vitrector prior to irrigation in the eyes of the other three
groups. Blood samples were also drawn at the time of
surgery from three patients in group 2.
Enzyme-linked immunosorbent assay for bevacizumab
Samples obtained from groups 1–4 underwent enzyme-linked
immunosorbent assay (ELISA) for bevacizumab. All steps of
the ELISA process were performed at room temperature.
Nunc 96-well Maxisorp plates (Thermo Scientific,
Rockford, IL, USA) were coated with 100 ul/well of
hrVEGF (Prospec, East Brunswick, NJ) at 2 ng/ul overnight,
followed by blocking at 0.5 % BSA in PBS for 1 hour.
Aqueous samples were diluted 1:4, and vitreous and serum
samples were diluted 1:2 in 1 % BSA in PBS with 0.05 %
Tween 20, and incubated for 2 hours. The wells were then
washed with 0.05 % Tween 20 in PBS and incubated for
30 min in goat anti-human IgG conjugated to horseradish
peroxidase (Jackson ImmunoResearch, West Grove, PA,
USA) diluted 1:10,000 in 1 % BSA in PBS with 0.05 %
Tween 20. The wells were then thoroughly washed before
development with 100 ul/well of TMB substrate (Pierce
Protein Biology, Rockford, IL, USA) for up to 30 minutes in
dark conditions. Absorbance was measured using optical
density (OD) values obtained from a microplate reader at
450 nm, with 620 nm as a reference. Bevacizumab
concentrations were compared to standard curves generated
with 1:2 serial dilutions from 400 ng/ml in 1 % BSA in PBS
with 0.05 % Tween 20 with 10 % human serum. This method
is very sensitive, and is capable of detecting bevacizumab
from a minimal concentration of 6.25 ng/ml. The standard
curve was generated from 6.25 ng/ml to 300 ng/ml, using
nonspecific human IgG as a negative control in place of the
bevacizumab. The detectable range of bevacizumab by this
method was therefore between 6.25 ng/ml and 300 ng/ml. For
quality control, all drawn samples were divided in two and
analyzed separately. The results of both samples of each
patient were then averaged.
Statistical analysis and pharmacokinetic calculations
Data were analyzed using SPSS for windows version 17.
Values are presented as mean ± standard deviation, unless
otherwise specified. The bevacizumab concentration was
multiplied by estimated volumes of 5.5 ml for vitreous
samples and 5,000 ml for serum samples in order to calculate
its mass [15, 16]. Half-life (T1/2) was calculated according to
first-order kinetics.
Results
A total of 22 eyes of 22 patients were included in this study.
There were eight males (36.3 %) and 14 females (73.7 %),
with a mean age of 69.2±10.2 years (range 53 to 89 years).
Their baseline characteristics and indications for surgery are
provided in Table 2.
Pharmacokinetics of topical bevacizumab
None of the eight patients in group 1 had received any prior
treatment with bevacizumab. Aqueous samples from their
eyes were obtained and assayed for bevacizumab. Their OD
values were 1.21±0.06 (range 0.038 to 0.246), corresponding
with no detectable bevacizumab. The eight patients in group 2
were also treated with topical bevacizumab, but on a longer
protocol. Vitreous samples were obtained from their eyes and
assayed for bevacizumab. Notably, two of these patients had
each received one intravitreal injection of bevacizumab
1.25 mg/0.05 ml prior to their enrollment into this study:
patient #11 (Table 2) received the injection 10 weeks prior to
surgery, and patient #12 received it 12 weeks prior to surgery.
The OD values in the vitreous samples from the six
group 2 patients who had never been treated with
bevacizumab were 0.287±0.19 (range 0.059 to 0.636),
corresponding with no detectable bevacizumab in any of
them. An aqueous sample was available from one of
these patients (patient #14), and no bevacizumab was
detected in it. Bevacizumab was, however, detected in
the vitreous samples from the two patients who were
previously treated intravitreally: the vitreal concentration
was 92.86 ng/ml in patient #11 and 89.3 ng/ml in
patient #12.
No pharmacokinetic calculations could be performed in the
aqueous or vitreous samples from patients who were only
treated topically, since there was no detectable bevacizumab.
The bevacizumab that was detected in the two patients in
group 2 was most likely due to the previous intravitreal
injections and not to the topical administration in this
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study. The T1/2 was 5.7 days for patient #11 and
7.3 days for patient #12.
Pharmacokinetics of intravitreal bevacizumab
In group 3, patients underwent intravitreal injection of
bevacizumab 1.25 mg/0.05 prior to PPV for the removal of
VH secondary due to PDR. None had been treated by
intravitreal bevacizumab prior to inclusion in this study.
Vitreous samples were obtained from their eyes and assayed
for bevacizumab. The time between intravitreal injection and
vitreal sampling varied between these three patients (Table 3),
and bevacizumab was detected in the vitreous samples of all
of them. In patient #17, PPV had been performed 2 months
after intravitreal injection, and a concentration of 19.12 ng/ml
of bevacizumab was detected. In patient #18, PPV had been
performed 1 month after intravitreal injection, and a
concentration of 107.27 ng/ml was detected. The T1/2 was
4.1 days for patient #17 and 2.5 days for patient #18.
Patient #19 was previously vitrectomized, and underwent a
standard core and peripheral vitrectomy due to a non-clearing
VH 1 year prior to enrollment. The patient was recruited to
this study before undergoing repeated PPV for recurrent VH
in the same eye, and received an intravitreal injection of
bevacizumab 1 week prior to surgery. A concentration of
149.37 ng/ml was detected in the vitreous sample obtained
during the study PPV, corresponding with a T1/2 of 0.66 days.
No trace of bevacizumab was detected in any of the
vitreous control samples from the three patients in group 4.
Systemic pharmacokinetics of topical and intravitreal
bevacizumab
Serum samples were available for patient #15 and patient #16
(group 2) who received topical bevacizumab, and no trace of
bevacizumab was detected in them. A serum sample was also
available for patient #18 (group 3), who received an
intravitreal bevacizumab injection 1 month prior to surgery:
a sample obtained at the time of surgery contained a serum
concentration of 44.85 ng/ml, corresponding with a systemic
T1/2 of 11.3 days for bevacizumab after intravitreal
administration.
Discussion
Bevacizumab was not detected in any of the eyes in which it
was administered topically. It was not detected in the aqueous
samples of any of the eight patients in group 1, nor in the
vitreous samples of the six patients in group 2 who had not
been previously treated by intravitreal injection. It was also
not detected in serum samples from two patients who were
treated solely by topical bevacizumab. These findings are
compatible with previous data from animal models, in which
corneal penetration was demonstrated as being extremely low,
even at higher doses and when following more prolonged
treatment protocols [11–14]. An intact corneal epithelium
was shown to provide an effective barrier that almost
Table 2 Baseline characteristics of the study patients
Patient no. Gender Age Group Surgery Indication
for surgery
1 M 70 1 Phaco Cataract
2 F 89 1 Phaco Cataract
3 F 72 1 Phaco Cataract
4 M 53 1 Phaco Cataract
5 F 87 1 Phaco Cataract
6 M 56 1 Phaco Cataract
7 F 78 1 Phaco Cataract
8 M 72 1 Phaco Cataract
9 F 77 2 PPV ERM
10 M 72 2 PPV ERM
11 M 69 2 PPV VH d/t PDR
12 F 75 2 PPV VH d/t PDR
13 F 63 2 PPV VH d/t PDR
14 F 66 2 PPV FTMH
15 M 53 2 PPV ERM
16 F 73 2 PPV VH d/t PDR
17 M 59 3 PPV VH d/t PDR
18 F 73 3 PPV VH d/t PDR
19 F 64 3 PPV VH d/t PDR
20 F 82 4 PPV ERM
21 F 56 4 PPV ERM
22 F 63 4 PPV FTMH
M = male; F = female; Phaco = phacoemulsification; PPV = pars plana
vitrectomy; ERM = epiretinal membrane; VH d/t PDR = vitreous
hemorrhage due to proliferative diabetic retinopathy; FTMH = full-
thickness macular hole.
Table 3 Intervals between intravitreal bevacizumab administration and
vitreal sampling during pars plana vitrectomy and calculated T1/2 values
for patients who received intravitreal bevacizumab
Patient Group Intervals (days) Calculated
T1/2 (days)
a
11 2 70 5.7
12 2 84 7.3
17 3 56 4.1
18 3 28 2.5
19b 3 7 0.66
a Half-life (T1/2) values for bevacizumab are provided.
b This patient had previously undergone vitrectomy in the study eye,
leading to a significantly reduced T1/2 value.
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completely excludes molecules larger than 1 nm [17]. Since
bevacizumab is approximately 12 nm long [13], its
penetration through healthy corneas is unlikely. Additionally,
it has been demonstrated that a monoclonal antibody is unable
to penetrate porcine cornea in vitro [18]. No pharmacokinetic
calculations could be performed in the current study, since no
bevacizumab was detected in eyes that were treated topically.
However, our results demonstrate that topical bevacizumab is
associated with virtually no penetration in human eyes with
intact corneas, corroborating previous findings in
experimental animal models.
It should be noted that corneal penetration has been
demonstrated to be significantly increased when corneal NV
or epithelial defects are present [13]. Several studies suggested
that topical bevacizumab may impair corneal epithelial
healing and cause stromal thinning after prolonged use [7,
19, 20]. It is also possible that the TWEEN buffer that is
present in the commercially available bevacizumab
preparation (Avastin®) acts as a detergent that can enhance
intraocular penetration [12, 21]. Therefore, it may be assumed
that its intraocular penetration will be higher in patients with
corneal NV and epithelial defects treated for long periods of
time with topical bevacizumab, but several studies have
reported very favorable safety profiles for topical
administration of bevacizumab in patients with corneal NV
[7–9, 22, 23]. An in vitro study demonstrated that the median
inhibitory concentration of bevacizumab is 22 ng/ml, and that
the minimal concentration that completely blocks all VEGF-
induced endothelial cell proliferation, migration, and
hyperpermeability is 500 ng/ml [24]. Even if corneal NV
and associated epithelial defects increase the risk of
bevacizumab penetration, it is probably unlikely to achieve
levels that can result in either effective intraocular activity or
adverse events. The implications of these findings are
encouraging, since corneal NV is an ocular surface disease,
and topical administration of bevacizumab will achieve a high
local therapeutic level [12, 17], with minimal risk for
intraocular or systemic adverse effects related to VEGF
inhibition.
Two of our five patients who were treated with intravitreal
injection of bevacizumab 1.25 mg/0.05 ml had also been
treated with topical bevacizumab according to the group 2
protocol, but the contribution of the latter to the detected level
in the vitreous was assumed to be negligible. The time
between intravitreal injection and vitreous sampling during
PPV and detected concentrations are specified in the Results
section and Table 3. Four of these eyes underwent PPV for the
first time in this study. Clearance of bevacizumab was
calculated to have a T1/2 that varied between 2.5 and 7.3 days,
with a mean of 4.9 days. These results are compatible with
previous pharmacokinetic studies of intravitreal bevacizumab
injection in non-vitrectomized human eyes, in which vitreal
T1/2 varied between 3 and 7.8 days [25–27]. They are also
comparable to previous studies on animal models that
reported the T1/2 of vitreal bevacizumab between 4.2 and
6.6 days [28–30].
A serum sample was available for one of our patients who
underwent intravitreal bevacizumab injection, and a systemic
T1/2 of 11.3 days was calculated. This value is comparable
with a previous animal study that reported a T1/2 of 12.9 days
[11]. Bevacizumab was not detected in serum samples from
two patients who were solely treated topically, demonstrating
that topical administration with punctual occlusion is
associated with virtually no systemic absorption of
bevacizumab.
One eye included in our study had previously been
vitrectomized. The detected vitreal concentration of
bevacizumab following intravitreal injection in that eye
resulted in a calculated T1/2 of 0.66 days. This T1/2 is
significantly shorter than that found in non-vitrectomized
eyes, both in our study and in reports by others [25–27]. It is
possible that the vitreous serves as a reservoir for injected
bevacizumab, and that its absence allows more rapid clearance
from the eye. The blood–brain and blood–retinal barriers
express neonatal Fc receptor that binds to the Fc portion of
antibodies and actively transports them into the systemic
circulation [31–33]. In vitrectomized eyes, bevacizumab
may more readily be transported out of the eye by this
mechanism. This is consistent with previous studies that
demonstrated significantly reduced T1/2 times after intravitreal
injection of triamcinolone acetonide in vitrectomized eyes in
both animal models and human eyes [34, 35].
Our search of the literature failed to reveal any publications
on the pharmacokinetics of bevacizumab in vitrectomized
human eyes. This is a novel finding, which may have
significant clinical implications. Bevacizumab is frequently
injected into previously vitrectomized eyes in clinical practice,
and its increased clearance may mandate more frequent
injections. This concept is supported by an earlier study that
reported a reduced effect of bevacizumab injections in
vitrectomized eyes [36].
Several limitations of this study warrant consideration.
First, topical bevacizumab was administered for only 1–
2 days, and it is possible that a regimen of more frequent
applications for a longer period of time might have resulted in
detectable intraocular bevacizumab levels. This is probably
unlikely, since the corneal epithelium was intact in all of our
studied eyes. Second, since no patients with corneal NV were
included, it is not possible to predict the pharmacokinetics of
topical bevacizumab in eyes with that pathology. Third, we
acknowledge that the number of patients who received
intravitreal bevacizumab was small, although there is a
precedent to describe as few as two patients in
pharmacokinetic studies in human eyes [25–28]. Fourth, we
note that the presence of vitreal hemorrhage in eyes that
received intravitreal bevacizumab injections may have altered
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its pharmacokinetics. However, this has not been established
in any study, and since all eyes treated intravitreally had VH,
we contend that comparing them is methodologically sound.
Finally, fixed volumes were assumed when calculating
bevacizumab amounts from vitreal and serum samples.
Although estimating individual vitreal and serum volumes
from individual patient’s axial length and weight might have
allowed more accurate calculations, their effect on T1/2
calculation would have been very small and clinically
insignificant.
In conclusion, our results indicate that topical bevacizumab
does not penetrate into the aqueous or vitreous following
short-term use. Our intention was to perform pharmacokinetic
calculations, but intraocular bevacizumab was not detected
following topical administration. These results are consistent
with previous studies, and support the growing body of
evidence attesting to efficient and safe topical use of
bevacizumab. Further studies of the pharmacokinetics in
patients with corneal NV are warranted. Additionally, our
results on vitreal and systemic T1/2 following intravitreal
bevacizumab injection corroborate previous studies. Finally,
our study demonstrates for the first time that the T1/2 of
intravitreal bevacizumab in a previously vitrectomized eye is
significantly reduced. More comprehensive studies of
bevacizumab pharmacokinetics in previously vitrectomized
eyes are warranted, and may lead to the formation of different
treatment regimens for such patients.
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